Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx, page-60

RAP traded in the price range 8.6c – 9.4c on the day immediately prior to receiving the Pfizer bid. Since that day the Company has received:

1) $4M in funding to jointly develop a Covid mass-scanning device from a company with regulatory influence and global commercialisation infrastructure;
2) global exposure and recognition on the standing of its unique diagnostic technologies;
3) patent approvals in Australia and Japan covering enhancement of its ResAppDx and ResAppCc cough detection devices; and
4) FDA approval to open up the US market for its sleep apnoea scanning device.

Once the share price becomes unrestricted through a successful No vote, in which direction do you really think it will head @ozgoldtrader ?